Antibody‐Drug Conjugates for the Treatment of Cancer

With over 20 antibody‐drug conjugates in clinical trials as well as a recently FDA‐approved drug, it is clear that this is becoming an important and viable approach for selectively delivering highly cytotoxic agents to tumor cells while sparing normal tissue. This review discusses the critical aspects for this approach with an emphasis on the properties of the linker between the antibody and the cytotoxic payload that are required for an effective antibody‐drug conjugate. Different linkers are illustrated with attention focused on (i) the specifics of attachment to the antibody, (ii) the polarity of the linker, (iii) the trigger on the linker that initiates cleavage from the drug, and (iv) the self‐immolative spacer that liberates the active payload. Future directions in the field are proposed.

[1]  Scott T Phillips,et al.  A self-immolative spacer that enables tunable controlled release of phenols under neutral conditions. , 2012, The Journal of organic chemistry.

[2]  E. Giné,et al.  Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Hartley.  The development of pyrrolobenzodiazepines as antitumour agents , 2011, Expert opinion on investigational drugs.

[4]  K. Gelmon,et al.  Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. , 1999, Journal of Clinical Oncology.

[5]  P. Frost,et al.  Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. , 2003, Current opinion in pharmacology.

[6]  Damon L. Meyer,et al.  Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.

[7]  B. Gunter,et al.  The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates , 2012, Molecular Cancer Therapeutics.

[8]  X. Wu,et al.  Tumor specific novel taxoid-monoclonal antibody conjugates. , 2002, Current medicinal chemistry.

[9]  Andrew T. Russell,et al.  Self-immolative linkers in polymeric delivery systems , 2011 .

[10]  P. Trail,et al.  Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. , 2002, Bioconjugate chemistry.

[11]  R. Chari,et al.  Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer. , 2012, Journal of medicinal chemistry.

[12]  N. Damle,et al.  Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma , 2006, Clinical Cancer Research.

[13]  X. H. Chen,et al.  Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  P. Trail,et al.  Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. , 1993, Science.

[15]  John M Lambert,et al.  Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.

[16]  R. Chari,et al.  Targeted cancer therapy: conferring specificity to cytotoxic drugs. , 2008, Accounts of chemical research.

[17]  M. Brechbiel,et al.  Targeting of Radio-Isotopes for Cancer Therapy , 2004, Cancer biology & therapy.

[18]  Yelena Kovtun,et al.  Semisynthetic maytansine analogues for the targeted treatment of cancer. , 2006, Journal of medicinal chemistry.

[19]  Kerry A Chester,et al.  Antibody–drug conjugates – a perfect synergy , 2012, Expert opinion on biological therapy.

[20]  Laurent Ducry,et al.  Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. , 2010, Bioconjugate chemistry.

[21]  A. Mountain,et al.  A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts. , 2005, Bioconjugate chemistry.

[22]  Hongsheng Xie,et al.  Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice , 2004, Journal of Pharmacology and Experimental Therapeutics.

[23]  J. Hartley,et al.  DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057 , 2012, Investigational New Drugs.

[24]  G. Dubowchik,et al.  Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. , 1998, Bioorganic & medicinal chemistry letters.

[25]  S. Shah,et al.  Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. , 1995, Cancer research.

[26]  M. Siegel,et al.  Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin .gamma.1I , 1987 .

[27]  H. W. Scheeren,et al.  "Cascade-release dendrimers" liberate all end groups upon a single triggering event in the dendritic core. , 2003, Angewandte Chemie.

[28]  A. Wahl,et al.  Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs. , 2002, The Journal of organic chemistry.

[29]  D. Neri,et al.  Antibody-drug conjugates: basic concepts, examples and future perspectives. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[30]  P. Trail,et al.  Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates. , 1999, Bioconjugate chemistry.

[31]  Irwin Hollander,et al.  Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. , 2002, Bioconjugate chemistry.

[32]  I. Hollander,et al.  Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. , 2008, Bioconjugate chemistry.

[33]  D. Kroll,et al.  Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues. , 2009, Bioconjugate chemistry.

[34]  D. Goldenberg,et al.  Designing immunoconjugates for cancer therapy , 2012, Expert opinion on biological therapy.

[35]  Damon L. Meyer,et al.  Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker. , 2007, Bioorganic & medicinal chemistry letters.

[36]  P. Trail,et al.  Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains. , 2002, Journal of medicinal chemistry.

[37]  I. Ojima.  Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads. , 2008, Accounts of chemical research.

[38]  Naresh Chennamsetty,et al.  Design and application of antibody cysteine variants. , 2010, Bioconjugate chemistry.

[39]  R. Lutz,et al.  Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. , 2006, Cancer research.

[40]  Paul Polakis,et al.  Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.

[41]  J. Knipe,et al.  Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. , 1998, Bioorganic & medicinal chemistry letters.

[42]  I. Bernstein,et al.  Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. , 2001, Blood.

[43]  John M Lambert,et al.  Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometry , 2005, Protein science : a publication of the Protein Society.

[44]  M. Cronauer,et al.  Re: Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2013 .

[45]  P. Polakis.  Arming antibodies for cancer therapy. , 2005, Current opinion in pharmacology.

[46]  V. Ramakrishnan,et al.  Investigational antibody-drug conjugates for hematological malignancies , 2011, Expert opinion on investigational drugs.

[47]  A. Younes,et al.  Brentuximab Vedotin (SGN-35) , 2011, Clinical Cancer Research.

[48]  E. Gillies,et al.  Design, synthesis, and cyclization of 4-aminobutyric acid derivatives: potential candidates as self-immolative spacers. , 2011, Organic & biomolecular chemistry.

[49]  I. Bernstein,et al.  An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. , 2002, Bioconjugate chemistry.

[50]  Rajeeva Singh,et al.  Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. , 2011, Journal of medicinal chemistry.

[51]  P. Schultz,et al.  Selective formation of covalent protein heterodimers with an unnatural amino acid. , 2011, Chemistry & biology.

[52]  Gerhard Moldenhauer,et al.  Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. , 2012, Journal of the National Cancer Institute.

[53]  Bonnie F. Sloane,et al.  Unraveling the role of proteases in cancer. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[54]  J. Walton,et al.  Ribosomal biosynthesis of the cyclic peptide toxins of Amanita mushrooms. , 2010, Biopolymers.

[55]  S. Hitchcock,et al.  Structural modifications that alter the P-glycoprotein efflux properties of compounds. , 2012, Journal of medicinal chemistry.

[56]  C. J. O’Donnell,et al.  Investigational antibody drug conjugates for solid tumors , 2011, Expert opinion on investigational drugs.

[57]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.